FDA July Meeting May Ease Peptide Compounding Limits as RFK Jr. Pushes Access, Experts Warn of Safety Risks

The U.S. Food and Drug Administration has scheduled a July 2026 advisory committee meeting to consider easing limits on more than seven injectable peptides — including influencer-favored BPC-157 — by asking outside advisers whether those substances should be added to the list of compounds that state-licensed pharmacies may legally prepare. The agency also plans to remove those peptides from a restrictive "do not compound" list while it seeks outside guidance. The move comes amid public advocacy from Robert F. Kennedy Jr., who told Joe Rogan he is a "big fan" of peptides and said he wants improved access from "ethical suppliers," and it has prompted sharp warnings from former FDA officials who say loosening compounding rules could undercut drug-approval incentives and create safety risks.

The debate occurs against a backdrop of rapid market growth and documented safety concerns: the U.S. peptide therapeutics market was valued at roughly $65.1 billion in 2024 and is projected to more than double by 2030, and regulators have already logged hundreds of adverse event reports tied to compounded GLP-1 products — about 520 reports for compounded semaglutide and 480 for compounded tirzepatide as of April 30, 2025. Small pilot data on BPC-157 showed tolerability in two healthy adults but comprehensive human safety and efficacy data remain limited, and analyses have flagged higher odds of adverse events and product-quality problems with compounded GLP-1s versus licensed products. Those realities, and the Biden-era FDA decision to add nearly 20 peptides to a "do not compound" list after staff and advisers cited "significant safety risks," underpin critics' concerns that broad compounding access could become a "wilder" market and a "profound threat" to the traditional approval system.

Public reaction is polarized. Physician-scientist voices on social platforms have warned that easing restrictions would permit unproven injectable drugs without sufficient safety data, while advocacy groups allied with RFK Jr. argue previous regulations pushed demand into unsafe black markets and that regulated compounding could improve access and quality. Other users pointed to studies they see as supportive of peptides' benefits, and some emphasized that regulated compounding would reduce contamination risks from online vendors. Coverage itself has shifted: earlier mainstream reporting focused on FDA efforts to tighten compounding limits and public advisories stressing that compounded drugs be reserved for patients lacking FDA-approved alternatives; recent stories from outlets including PBS and Fox have highlighted the agency's planned reversal to convene advisers and temporarily delist specific peptides, with reporting emphasizing both the politically salient push from RFK Jr. and renewed concerns about advisory-panel vacancies that critics say could affect the outcome.